![]() in 1975, forming Sigma-Aldrich Corporation. When changing trends in chemical research confirmed the synergy to be realized from their complementary product offerings, Aldrich Chemical Co. For many years, the two companies grew independently, Sigma serving primarily biochemists and Aldrich serving organic chemists. Both companies started with the production and distribution of a single proprietary chemical: Adenosine triphosphate (ATP) by Sigma and 1-methyl-3- nitro-1-nitrosoguanidine (MNNG) by Aldrich. Sigma and Aldrich were founded separately in 19, respectively, to supply biochemicals and chemicals to research scientists in the U.S. Today, Merck KGaA, Darmstadt, Germany is a global pharmaceutical, chemical and life science company with a history that began in 1668 and a future shaped by approximately 50,000 employees in 66 countries.įor the full history, click here. New ultrapure products were sold the first biotechnology production process was introduced and Merck KGaA, Darmstadt, Germany entered the market. As the century progressed, so did the company. The transformation of Merck KGaA, Darmstadt, Germany to a research-driven industrial company was marked in 1827 when Emanuel Merck isolated and characterized alkaloids for distribution to chemists. “The fact that (the Merck family) are not taking a big step further into pharma shows that continuous returns on their investment over time are certainly important to the family,” said analyst Ulrich Huwald at brokerage Warburg.Īt about 6 billion euros in annual sales, Merck’s pharmaceuticals unit is well outside the global top 20, having suffered a series of drug development setbacks such as with an experimental cancer vaccine known as tecemotide, or Stimuvax, which did not come to market due to poor study results.In 1668, Friedrich Jacob Merck purchased the Engel Pharmacy in Darmstadt, Germany. The deal would more than double the lab equipment unit’s adjusted core earnings, even without such synergy gains including them, the increase would be 139 percent, based on proforma 2013 results. It said it was too early to say if any jobs would be cut. ![]() Merck expects the tie-up, funded from about 2 billion euros in cash reserves and the issue of new debt, to yield annual synergy benefits of 260 million euros ($334 million) within three years after closing, by measures such as streamlining manufacturing, administration and research. Shares in Merck, which initially turned negative on the news, closed 4.3 percent higher at 72.63 euros, against a 0.2 percent lower European chemicals index. Merck still sees investment grade ratings after Sigma-Aldrich deal Merck said it will acquire Sigma-Aldrich shares for $140 apiece, a 36 percent premium over the one-month average closing price and a 37 percent more than the latest closing price of $102.37 on Friday, Sept. The deal was approved by Sigma-Aldrich’s management but still needs acceptance from more than 50 percent of the target’s shareholders. Merck, which has been hit by several drug development failures, said it was happy for its own pharmaceuticals business to remain a medium-sized entity. “With this acquisition we have the opportunity to turn one of our most reliable businesses into a core earnings contributor,” said finance chief Marcus Kuhnert. The deal helps Merck, 70 percent controlled by the descendants of its 17th century founder, to focus more on supplying drugmakers and academic institutions with chemicals and services, seen as offering a steadier income stream than drug development. A branch of drugs and chemicals group Merck is pictured in central German city of Darmstadt March 7, 2012. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |